Jan M Hughes-Austin1, Ryan W Gan2, Kevin D Deane3, Michael H Weisman4, M Kristen Demoruelle3, Jeremy Sokolove5,6, William H Robinson5,6, V Michael Holers3, Jill M Norris2, Joachim H Ix7,8. 1. Department of Orthopaedic Surgery, School of Medicine, University of California, San Diego, La Jolla, California, USA. 2. Department of Epidemiology, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA. 3. Department of Rheumatology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA. 4. Division of Rheumatology, Department of Medicine, Cedars-Sinai, Los Angeles, California, USA. 5. Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA. 6. VA Palo Alto Health Care System, Palo Alto, California, USA. 7. Division of Nephrology-Hypertension, Department of Medicine, School of Medicine, University of California, San Diego, La Jolla, California, USA. 8. VA San Diego Health Care System, San Diego, California, USA.
Abstract
BACKGROUND: Hypertension is more common in patients with rheumatoid arthritis (RA) than in the general population. It is unknown whether hypertension is due to RA-related medications or the disease itself. Therefore, we sought to investigate associations between RA-related autoantibodies, specifically antibodies to citrullinated protein antigens (ACPA) and systolic blood pressure (SBP) and diastolic blood pressure (DBP) in first-degree relatives of RA patients, who were free of RA and RA-related medications. We hypothesized that a greater number of detectable ACPA would be associated with high SBP and DBP, independent of other risk factors in these first-degree relatives. METHODS: We evaluated associations between ACPA and SBP and DBP in a cross-sectional study of 72 first-degree relatives (defined as parent, child, or sibling) of RA patients. Fifteen ACPA were measured using a Bio-Plex bead-based assay; each was dichotomized as positive/negative based on pre-specified cut-points. Analysis of covariance was used to evaluate associations between ACPA positivity and SBP and DBP, adjusting for age, sex, race, body mass index (BMI), pack-years of smoking, high sensitivity C-reactive protein (hsCRP), and current use of anti-hypertensive medications. RESULTS: Average age was 51 and 69% were women. Mean SBP was 119 ± 18 and DBP was 74 ± 9 mm Hg. Thirty-three (46%) first-degree relatives were positive for ≥1 ACPA; and were younger, had lower BMI, more pack-years of smoking, and higher hsCRP concentrations compared to ACPA negative first-degree relatives. For each additional positive ACPA, SBP was 0.98 ± 0.5 mm Hg (p = 0.05) higher, and DBP was 0.66 ± 0.3 mm Hg (p = 0.04) higher. Anti-cit-fibrinogen A (211-230) positive and anti-cit-filaggrin positive first-degree relatives had 11.5 and 13.9 mm Hg higher SBP (p = 0.02) respectively. Anti-cit-clusterin, cit-filaggrin, and cit-vimentin positive first-degree relatives had 7-8 mm Hg higher DBP (p = 0.03, 0.05, 0.05 respectively), compared to being negative for these individual ACPA. Consistent with associations between ACPA, SBP, and DBP, anti-cyclic citrullinated peptides (anti-CCP2) positive first-degree relatives had 16.4± (p = 0.03) higher SBP and 12.1± mm Hg (p = 0.01) higher DBP than anti-CCP2 negative first-degree relatives. CONCLUSION: In first-degree relatives without RA, ACPA positivity is associated with higher SBP and DBP. Subclinical autoimmune processes and ACPA may play a role in the vascular changes potentially leading to hypertension prior to RA onset.
BACKGROUND:Hypertension is more common in patients with rheumatoid arthritis (RA) than in the general population. It is unknown whether hypertension is due to RA-related medications or the disease itself. Therefore, we sought to investigate associations between RA-related autoantibodies, specifically antibodies to citrullinated protein antigens (ACPA) and systolic blood pressure (SBP) and diastolic blood pressure (DBP) in first-degree relatives of RA patients, who were free of RA and RA-related medications. We hypothesized that a greater number of detectable ACPA would be associated with high SBP and DBP, independent of other risk factors in these first-degree relatives. METHODS: We evaluated associations between ACPA and SBP and DBP in a cross-sectional study of 72 first-degree relatives (defined as parent, child, or sibling) of RA patients. Fifteen ACPA were measured using a Bio-Plex bead-based assay; each was dichotomized as positive/negative based on pre-specified cut-points. Analysis of covariance was used to evaluate associations between ACPA positivity and SBP and DBP, adjusting for age, sex, race, body mass index (BMI), pack-years of smoking, high sensitivity C-reactive protein (hsCRP), and current use of anti-hypertensive medications. RESULTS: Average age was 51 and 69% were women. Mean SBP was 119 ± 18 and DBP was 74 ± 9 mm Hg. Thirty-three (46%) first-degree relatives were positive for ≥1 ACPA; and were younger, had lower BMI, more pack-years of smoking, and higher hsCRP concentrations compared to ACPA negative first-degree relatives. For each additional positive ACPA, SBP was 0.98 ± 0.5 mm Hg (p = 0.05) higher, and DBP was 0.66 ± 0.3 mm Hg (p = 0.04) higher. Anti-cit-fibrinogen A (211-230) positive and anti-cit-filaggrin positive first-degree relatives had 11.5 and 13.9 mm Hg higher SBP (p = 0.02) respectively. Anti-cit-clusterin, cit-filaggrin, and cit-vimentin positive first-degree relatives had 7-8 mm Hg higher DBP (p = 0.03, 0.05, 0.05 respectively), compared to being negative for these individual ACPA. Consistent with associations between ACPA, SBP, and DBP, anti-cyclic citrullinated peptides (anti-CCP2) positive first-degree relatives had 16.4± (p = 0.03) higher SBP and 12.1± mm Hg (p = 0.01) higher DBP than anti-CCP2 negative first-degree relatives. CONCLUSION: In first-degree relatives without RA, ACPA positivity is associated with higher SBP and DBP. Subclinical autoimmune processes and ACPA may play a role in the vascular changes potentially leading to hypertension prior to RA onset.
Authors: Darcy S Majka; Thanh-Huyen T Vu; Richard M Pope; Marius Teodorescu; Elizabeth W Karlson; Kiang Liu; Rowland W Chang Journal: Arthritis Care Res (Hoboken) Date: 2017-02 Impact factor: 4.794
Authors: Chenglong Han; Don W Robinson; Monica V Hackett; L Clark Paramore; Kathy H Fraeman; Mohan V Bala Journal: J Rheumatol Date: 2006-09-01 Impact factor: 4.666
Authors: Jason R Kolfenbach; Kevin D Deane; Lezlie A Derber; Colin O'Donnell; Michael H Weisman; Jane H Buckner; Vivian H Gersuk; Shan Wei; Ted R Mikuls; James O'Dell; Peter K Gregersen; Richard M Keating; Jill M Norris; V Michael Holers Journal: Arthritis Rheum Date: 2009-12-15
Authors: Jan M Hughes-Austin; Kevin D Deane; Lezlie A Derber; Jason R Kolfenbach; Gary O Zerbe; Jeremy Sokolove; Lauren J Lahey; Michael H Weisman; Jane H Buckner; Ted R Mikuls; James R O'Dell; Richard M Keating; Peter K Gregersen; William H Robinson; V Michael Holers; Jill M Norris Journal: Ann Rheum Dis Date: 2012-08-21 Impact factor: 19.103
Authors: Nisha I Parikh; Michael J Pencina; Thomas J Wang; Emelia J Benjamin; Katherine J Lanier; Daniel Levy; Ralph B D'Agostino; William B Kannel; Ramachandran S Vasan Journal: Ann Intern Med Date: 2008-01-15 Impact factor: 25.391
Authors: Annet Kirabo; Vanessa Fontana; Ana P C de Faria; Roxana Loperena; Cristi L Galindo; Jing Wu; Alfiya T Bikineyeva; Sergey Dikalov; Liang Xiao; Wei Chen; Mohamed A Saleh; Daniel W Trott; Hana A Itani; Antony Vinh; Venkataraman Amarnath; Kalyani Amarnath; Tomasz J Guzik; Kenneth E Bernstein; Xiao Z Shen; Yu Shyr; Sheau-chiann Chen; Raymond L Mernaugh; Cheryl L Laffer; Fernando Elijovich; Sean S Davies; Heitor Moreno; Meena S Madhur; Jackson Roberts; David G Harrison Journal: J Clin Invest Date: 2014-09-17 Impact factor: 14.808